The use of small peptides in the diagnosis and treatment of hepatocellular carcinoma

Protein and Peptide Letters

Volumn 16, Issue 5, 2009, Pages 530-538

  Tsang, Felice H ^a   Lee, Nikki P ^a   Luk, John M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diagnosis; Hepatocellular carcinoma; Liver cancer; Protein peptide; Therapy

Indexed keywords

PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMISTRY; HUMAN; LIVER CELL CARCINOMA; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 67649336785     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986609788167860     Document Type: Article

References (70)

1. P arkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA. Cancer J. Clin., 2005, 55(2), 74-108.
2. Bosch, F. X.; Ribes, J.; Diaz, M.; Cleries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology, 2004, 727(5 Suppl 1), S5-S16.
3. Blum, H. E. Treatment of hepatocellular carcinoma. Best Pract.Res. Clin. Gastroenterol., 2005, 79(1), 129-45.
4. Shetty, K.; Timmins, K.; Brensinger, C.; Furth, E. E.; Rattan, S.;Sun, W.; Rosen, M.; Soulen, M.; Shaked, A.; Reddy, K. R.; Olthoff, K. M. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl., 2004, 70(7), 911-8.
5. Livraghi, T.; Meloni, F.; Morabito, A.; Vettori, C. Multimodal image-guided tailored therapy of early and intermediate hepatocel- lular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl., 2004, 70(2 Suppl 1), S98-106.
6. Lo, C. M.; Ngan, H.; Tso, W. K.; Liu, C. L.; Lam, C. M.; Poon, R.T.; Fan, S. T.; Wong, J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002, 35(5), 1164-71.
7. Mathurin, P.; Rixe, O.; Carbonell, N.; Bernard, B.; Cluzel, P.;Bellin, M. F.; Khayat, D.; Opolon, P.; Poynard, T. Review article: Overview of medical treatments in unresectable hepatocellular car- cinoma--an impossible meta-analysis? Aliment Pharmacol. Ther., 1998, 72(2), 111-26.
8. Chow, P. K.; Tai, B. C.; Tan, C. K.; Machin, D.; Win, K. M.; Johnson, P. J.; Soo, K. C. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology, 2002, 36(5), 1221-6.
9. Yuen, M. F.; Poon, R. T.; Lai, C. L.; Fan, S. T.; Lo, C. M.; Wong,K. W.; Wong, W. M.; Wong, B. C. A randomized placebo- controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology, 2002, 36(3), 687-91.
10. Yang, T. S.; Lin, Y. C.; Chen, J. S.; Wang, H. M.; Wang, C. H. Phase II study of gemcitabine in patients with advanced hepatocel- lular carcinoma. Cancer, 2000, 89(4), 750-6.
11. Palmieri, G.; Gridelli, C.; Pepe, R.; Airoma, G.; Iaffaioli, R. V.; Frasci, G.; Caponigro, F.; Bianco, A. R. Partial response of metas- tatic hepatocellular carcinoma after treatment with thymostimulin. Tumori., 1990, 76(1), 61-3.
12. Yuen, M. F.; Lai, C. L. Serological markers of liver cancer. Best Pract. Res. Clin. Gastroenterol., 2005, 79(1), 91-9.
13. Peterson, M. S.; Baron, R. L. Radiologic diagnosis of hepatocellu- lar carcinoma. Clin. Liver Dis., 2001, 5(1), 123-44.
14. Sun, S.; Lee, N. P.; Poon, R. T.; Fan, S. T.; He, Q. Y.; Lau, G. K.; Luk, J. M. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int., 2007, 27(8), 1021-38.
15. Santamaria, E.; Munoz, J.; Fernandez-Irigoyen, J.; Prieto, J.; Cor- rales, F. J. Toward the discovery of new biomarkers of hepatocellu- lar carcinoma by proteomics. Liver Int., 2007, 27(2), 163-73.
16. Marrero, J. A.; Lok, A. S. Newer markers for hepatocellular carcinoma. Gastroenterology, 2004, 727(5 Suppl 1), S113-9.
17. Lee, N. P.; Cheung, S. T.; Poon, R. T.; Fan, S. T.; Luk, J. M. Ge- nomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomarkers Med., 2007, 7, 273-284.
18. Patel, L. N.; Zaro, J. L.; Shen, W. C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res., 2007, 24(11), 1977-92.
19. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24(4), 389-427.
20. Parmiani, G.; Castelli, C.; Dalerba, P.; Mortarini, R.; Rivoltini, L.; Marincola, F. M.; Anichini, A. Cancer immunotherapy with pep- tide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst., 2002, 94(11), 805-18.
21. Jiang, Y. Q.; Wang, H. R.; Li, H. P.; Hao, H. J.; Zheng, Y. L.; Gu, J. Targeting of hepatoma cell and suppression of tumor growth by a novel 12mer peptide fused to superantigen TSST-1. Mol. Med., 2006, 72(4-6), 81-7.
22. Gusarova, G. A.; Wang, I. C.; Major, M. L.; Kalinichenko, V. V.; Ackerson, T.; Petrovic, V.; Costa, R. H. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest., 2007, 777(1), 99-111.
23. Komori, H.; Nakatsura, T.; Beppu, T.; Nishimura, Y.; Baba, H. [Possibilities of glypican-3-specific immunotherapy for hepatocel- lular carcinoma]. Gan ToKagaku Ryoho., 2006, 33(12), 1742-4.
24. Zhang, B.; Zhang, Y.; Wang, J.; Zhang, Y.; Chen, J.; Pan, Y.; Ren, L.; Hu, Z.; Zhao, J.; Liao, M.; Wang, S. Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library. Mol. Med., 2007, 73(5-6), 246-54.
25. Wang, X. H.; Qin, Y.; Hu, M. H.; Xie, Y. Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses. World J. Gastroenterol., 2005, 77(36), 5614-20.
26. Takafuji, V.; Forgues, M.; Unsworth, E.; Goldsmith, P.; Wang, X. W. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene, 2007, 26(44), 6361-71.
27. Winkler, H.; Fischer-Colbrie, R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience, 1992, 49(3), 497-528.
28. Sanchez-Margalet, V.; Gonzalez-Yanes, C.; Najib, S. Pancreas- tatin, a chromogranin A-derived peptide, inhibits DNA and protein synthesis by producing nitric oxide in HTC rat hepatoma cells. J. Hepatol., 2001, 35(1), 80-5.
29. Luk, J. M.; Wong, K. F. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma. Clin. Exp. Pharmacol. Physiol., 2006, 33(5-6), 482-8.
30. Schally, A. V. Oncological applications of somatostatin analogues. Cancer Res., 1988, 48(24 Pt 1), 6977-85.
31. Schally, A. V.; Comaru-Schally, A. M.; Nagy, A.; Kovacs, M.; Szepeshazi, K.; Plonowski, A.; Varga, J. L.; Halmos, G. Hypotha- lamic hormones and cancer. Front. Neuroendocrinol., 2001, 22(4), 248-91.
32. Moody, T. W.; Chan, D.; Fahrenkrug, J.; Jensen, R. T. Neuropep- tides as autocrine growth factors in cancer cells. Curr. Pharm. Des., 2003, 9(6), 495-509.
33. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T. J.; Pless. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci., 1982, 37(11), 1133-40.
34. De Jong, M.; Bernard, B. F.; De Bruin, E.; Van Gameren, A.; Bak- ker, W. H.; Visser, T. J.; Macke, H. R.; Krenning, E. P. Internaliza-tion of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3] oc-treotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl. Med. Commun., 1998, 79(3), 2838.
35. Benjegard, S. A.; Forssell-Aronsson, E.; Wangberg, B.; Skanberg, J.; Nilsson, O.; Ahlman, H. Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector. Eur. J. Nucl. Med., 2001, 28(10), 1456-62.
36. Schally, A. V.; Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol., 1999, 747(1), 1-14.
37. Green, M.; Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans- activator protein. Cell, 1988, 55(6), 1179-88.
38. Derossi, D.; Joliot, A. H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem., 1994, 269(14), 10444-50.
39. Cao, G.; Pei, W.; Ge, H.; Liang, Q.; Luo, Y.; Sharp, F. R.; Lu, A.; Ran, R.; Graham, S. H.; Chen, J. In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J. Neurosci., 2002, 22(13), 5423-31.
40. Rittner, K.; Benavente, A.; Bompard-Sorlet, A.; Heitz, F.; Divita, G.; Brasseur, R.; Jacobs, E. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol. Ther., 2002, 5(2), 104-14.
41. Thoren, P. E.; Persson, D.; Isakson, P.; Goksor, M.; Onfelt, A.Norden, B. Uptake of analogs of penetratin, Tat(48-60) and oli- goarginine in live cells. Biochem. Biophys. Res. Commun., 2003, 307(1), 100-7.
42. Jarver, P.; Langel, U. Cell-penetrating peptides-- a brief introduction. Biochim. Biophys. Acta., 2006, 7 758(3), 260-3.
43. Derossi, D.; Calvet, S.; Trembleau, A.; Brunissen, A.; Chassaing, G.; Prochiantz, A. Cell internalization of the third helix of the An- tennapedia homeodomain is receptor-independent. J. Biol. Chem., 1996, 277(30), 18188-93.
44. Langel, U., Cell-penetrating peptides : processes and applications. CRC Press: Boca Raton, FL, 2002; p 406.
45. Vives, E.; Richard, J. P.; Rispal, C.; Lebleu, B. TAT peptide internalization: seeking the mechanism of entry. Curr. Protein Pept. Sci., 2003, 4(2), 125-32.
46. Richard, J. P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M. J.; Chernomordik, L. V.; Lebleu, B. Cell-penetrating pep- tides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem., 2003, 278(1), 585-90.
47. Lindgren, M.; Hallbrink, M.; Prochiantz, A.; Langel, U. Cell- penetrating peptides. Trends Pharmacol. Sci., 2000, 27(3), 99-103.
48. Lechardeur, D.; Lukacs, G. L. Nucleocytoplasmic transport of plasmid DNA: a perilous journey from the cytoplasm to the nucleus. Hum. Gene Ther., 2006, 7 7(9),882-9.
49. Lindgren, M.; Rosenthal-Aizman, K.; Saar, K.; Eiriksdottir, E.; Jiang, Y.; Sassian, M.; Ostlund, P.; Hallbrink, M.; Langel, U. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem. Pharmacol.,2006, 77(4), 416-25.
50. Rousselle, C.; Clair, P.; Lefauconnier, J. M.; Kaczorek, M.Scherrmann, J. M.; Temsamani, J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector mediated strategy. Mol. Pharmacol., 2000, 57(4), 679-86.
51. Fahraeus, R.; Lain, S.; Ball, K. L.; Lane, D. P. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene, 1998, 76(5), 587-96.
52. Hosotani, R.; Miyamoto, Y.; Fujimoto, K.; Doi, R.; Otaka, A.; Fujii, N.; Imamura, M. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin. Cancer Res.2002, 8(4), 1271-6.
53. Ignatovich, I. A.; Dizhe, E. B.; Pavlotskaya, A. V.; Akifiev, B. N.;Burov, S. V.; Orlov, S. V.; Perevozchikov, A. P. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis mediated pathways. J. Biol. Chem., 2003, 278(43), 42625-36.
54. Khalil, I. A.; Futaki, S.; Niwa, M.; Baba, Y.; Kaji, N.; Kamiya, H.; Harashima, H. Mechanism of improved gene transfer by the N- terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther., 2004, 77(7), 636-44.
55. Dietz, G. P.; Bahr, M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci., 2004, 27(2), 85131.
56. Williamson, N. A.; Rossjohn, J.; Purcell, A. W. Tumors reveal their secrets to cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 2006, 703(40), 14649-50.
57. Mayordomo, J. I.; Loftus, D. J.; Sakamoto, H.; De Cesare, C. M.; Appasamy, P. M.; Lotze, M. T.; Storkus, W. J.; Appella, E.; DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 1996, 783(4), 1357-65.
58. Gottschalk, S.; Heslop, H. E.; Rooney, C. M. Adoptive immuno- therapy for EBV-associated malignancies. Leuk. Lymphoma, 2005, 46(1), 1-10.
59. Scanlan, M. J.; Gure, A. O.; Jungbluth, A. A.; Old, L. J.; Chen, Y T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev., 2002, 788, 22-32.
60. Wang, R. F.; Wang, X.; Rosenberg, S. A. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J. Exp. Med., 1999, 789(10), 1659-68.
61. Chiari, R.; Hames, G.; Stroobant, V.; Texier, C.; Maillere, B.; Boon, T.; Coulie, P. G. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res., 2000, 60(17), 4855-63.
62. Gilboa, E. The makings of a tumor rejection antigen. Immunity, 1999, 77(3), 263-70.
63. Dallal, R. M.; Lotze, M. T. The dendritic cell and human cancer vaccines. Curr. Opin. Immunol., 2000, 72(5), 583-8.
64. Mayordomo, J. I.; Zorina, T.; Storkus, W. J.; Zitvogel, L.; Celluzzi C.; Falo, L. D.; Melief, C. J.; Ildstad, S. T.; Kast, W. M.; Deleo, A.B.; et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1995, 7(12), 1297-302.
65. Srivastava, P. K. Immunotherapy of human cancer: lessons from mice. Nat. Immunol., 2000, 7(5), 363-6.
66. Srivastava, P. K.; Amato, R. J. Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine, 2001, 79(17-19), 2590-7.
67. Cui, Q.; Jiang, W.; Wang, Y.; Lv, C.; Luo, J.; Zhang, W.; Lin, F.; Yin, Y.; Cai, R.; Wei, P.; Qian, C. Transfer of suppressor of cyto- kine signaling 3 by an oncolytic adenovirus induces potential anti- tumor activities in hepatocellular carcinoma. Hepatology, 2008, 47(1), 105-12.
68. Shang, X. Y.; Chen, H. S.; Zhang, H. G.; Pang, X. W.; Qiao, H.; Peng, J. R.; Qin, L. L.; Fei, R.; Mei, M. H.; Leng, X. S.; Gnjatic, S.; Ritter, G.; Simpson, A. J.; Old, L. J.; Chen, W. F. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res., 2004, 70(20), 6946-55.
69. Zhang, Y.; Song, S.; Liu, C.; Wang, Y.; Xian, X.; He, Y.; Wang, J.Liu, F.; Sun, S. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo. Cell Immunol., 2007, 247(1), 18-27.
70. Butterfield, L. H.; Ribas, A.; Dissette, V. B.; Lee, Y.; Yang, J. Q.De la Rocha, P.; Duran, S. D.; Hernandez, J.; Seja, E.; Potter, D.M.; McBride, W. H.; Finn, R.; Glaspy, J. A.; Economou, J. S. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein pep- tides. Clin. Cancer Res., 2006, 72(9), 2817-25.